^
    8ms
    Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib (clinicaltrials.gov)
    P2, N=4, Terminated, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | N=104 --> 4 | Recruiting --> Terminated; Sponsor R&D Strategy Adjustment
    Enrollment change • Trial termination
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Xalkori (crizotinib) • alkotinib (ZG0418)
    10ms
    Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=17, Completed, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting --> Completed
    Trial completion • Metastases
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Xalkori (crizotinib) • alkotinib (ZG0418)
    1year
    Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib (clinicaltrials.gov)
    P2, N=104, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Xalkori (crizotinib) • alkotinib (ZG0418)
    over1year
    Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Xalkori (crizotinib) • alkotinib (ZG0418)
    2years
    Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib (clinicaltrials.gov)
    P2, N=104, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Xalkori (crizotinib) • alkotinib (ZG0418)
    2years
    A Phase I Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: May 2022 --> May 2023 | Trial primary completion date: Feb 2022 --> Feb 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Xalkori (crizotinib) • alkotinib (ZG0418)
    over3years
    A Phase I Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: May 2021 --> May 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Xalkori (crizotinib) • alkotinib (ZG0418)
    over4years
    A Phase I Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: May 2020 --> May 2021 | Trial primary completion date: Feb 2020 --> Feb 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Xalkori (crizotinib) • alkotinib (ZG0418)